Sunosi FDA Approval History
Last updated by Judith Stewart, BPharm on March 31, 2019.
FDA Approved: Yes (First approved March 20, 2019)
Brand name: Sunosi
Generic name: solriamfetol
Dosage form: Tablets
Company: Jazz Pharmaceuticals plc
Treatment for: Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome
Sunosi (solriamfetol) is a selective dopamine and norepinephrine reuptake inhibitor (DNRI) for the treatment of excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA).
- Sunosi tablets are taken once daily upon awakening.
- Because of the potential of Sunosi to interfere with scheduled sleep, doses should not be taken within 9 hours of planned bedtime .
- Sunosi is a federally controlled substance because it has the potential to be abused. Sunosi tablets should always be stored in a secure place.
- Common side effects include headache, nausea, decreased appetite, insomnia, and anxiety.
Development timeline for Sunosi
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
